Mitochondrial Metabolism and Cancer

  title={Mitochondrial Metabolism and Cancer},
  author={Frank Weinberg and Navdeep S. Chandel},
  journal={Annals of the New York Academy of Sciences},
Historically, it has been assumed that glycolytic metabolism, not mitochondrial metabolism, is essential for tumor cell proliferation. However, most tumor cells have functional mitochondria, and recent studies suggest that the citric acid cycle (TCA) cycle intermediates are precursors for synthesis of nucleotides, lipids, and amino acids. Here we review the accumulating evidence that mitochondrial metabolism plays an essential role in tumor cell proliferation. 
Breast Cancer Metabolism and Mitochondrial Activity: The Possibility of Chemoprevention with Metformin
Metabolic reprogramming refers to the ability of cancer cells to alter their metabolism in order to support the increased energy request due to continuous growth, rapid proliferation, and other
Targeting Mitochondrial Enzymes in Pancreatic Cancer
Deregulated mitochondrial enzymes not only participate in the metabolic reprogramming of tumor cells but also modulate cellular processes involved in tumor proliferation and progression.
Targeting Mitochondria: A Powerhouse Approach to Cancer Treatment
This chapter would focus on the altered mitochondrial bioenergetics in tumour cells and their therapeutic implications.
Hypoxia and mitochondrial oxidative metabolism.
Relevance of mitochondrial genetics and metabolism in cancer development.
The threshold model the authors propose, based on the population-like dynamics of mitochondrial genetics, implies that below threshold complex I is present and functioning correctly, thus favoring tumor growth, whereas above threshold, whencomplex I is not assembled, tumor growth is arrested.
Metabolic Heterogeneity of Cancer Cells: An Interplay between HIF-1, GLUTs, and AMPK
The present review focuses on cross-talks between HIF-1, glucose transporters, and AMPK with other regulatory proteins including oncogenes such as c-Myc, p53, and KRAS; growth factor-initiated protein kinase B (PKB)/Akt, phosphatidyl-3-kinase (PI3K), and mTOR signaling pathways; and tumor suppressors in controlling cancer cell metabolism.
Friend or foe? Mitochondria as a pharmacological target in cancer treatment.
This comprehensive review covers not only the recent discoveries of the roles of mitochondria in cancer development, progression and therapeutic implications but also the findings regarding emerging mitochondrial therapeutic targets and mitochondria-targeted agents.
Targeting Mitochondria of Cancer Cells: Mechanisms and Compounds
Mitochondria are being proposed and tested as plausible targets for cancer therapy because they comprise potent inducers of apoptosis, and their differences compared to mitochondria of normal cells give hope to the potential establishment of efficient and selective anti-cancer agents.
mTOR signaling in cellular and organismal energetics.


Oncogenic alterations of metabolism.
p53 Regulates Mitochondrial Respiration
It is shown that p53, one of the most frequently mutated genes in cancers, modulates the balance between the utilization of respiratory and glycolytic pathways, and Synthesis of Cytochrome c Oxidase 2 (SCO2) is identified as the downstream mediator of this effect.
Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis
Transformed cells exhibit a high rate of glutamine consumption that cannot be explained by the nitrogen demand imposed by nucleotide synthesis or maintenance of nonessential amino acid pools, and glutamine metabolism provides a carbon source that facilitates the cell's ability to use glucose-derived carbon and TCA cycle intermediates as biosynthetic precursors.
c-Myc suppression of miR-23 a / b enhances mitochondrial glutaminase expression and glutamine metabolism
The c-Myc (hereafter referred to as Myc) oncogenic transcription factor, which is known to regulate microRNAs and stimulate cell proliferation, transcriptionally represses miR-23a and miB-23b, resulting in greater expression of their target protein, mitochondrial glutaminase, in human P-493 B lymphoma cells and PC3 prostate cancer cells.
Why do cancers have high aerobic glycolysis?
It is proposed that persistent metabolism of glucose to lactate even in aerobic conditions is an adaptation to intermittent hypoxia in pre-malignant lesions, which leads to microenvironmental acidosis requiring evolution to phenotypes resistant to acid-induced cell toxicity.
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
It is demonstrated that M2 expression is necessary for aerobic glycolysis and that this metabolic phenotype provides a selective growth advantage for tumour cells in vivo.
Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells
The results suggest that the fate of normal human cells should be considered in evaluating nutrient deprivation as a strategy for cancer therapy, and that understanding how glutamine metabolism is linked to cell viability might provide new approaches for treatment of cancer.
Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction
It is reported that the transcriptional regulatory properties of the oncogene Myc coordinate the expression of genes necessary for cells to engage in glutamine catabolism that exceeds the cellular requirement for protein and nucleotide biosynthesis, resulting in the reprogramming of mitochondrial metabolism to depend on glutaminolysis to sustain cellular viability and TCA cycle anapleurosis.